Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Breeze Meds vs REMEVi

Breeze Meds
Graded #55

Lower grade

vs+1.0999999999999943
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 72.4/100, but only just.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated. Breeze Meds is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBreeze Meds +15
72
57
Dose & formulationREMEVi +17
66
83
Clinical oversightREMEVi +10
76
86
Labs & monitoringBreeze Meds +5
60
55
FulfillmentREMEVi +13
84
97
Contract termsBreeze Meds +17
86
69
Breeze Meds · left barREMEVi · right bar

The numbers

MetricBreeze MedsREMEVi
WeighScore72.4/10073.5/100
GradeCC
Scorecard rank#55#70
SemaglutideFrom $199/mo$219/mo
TirzepatideFrom $299/mo first month, $399/mo thereafter$319/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Breeze Meds

Graded #55 · C

Strengths

  • Nothing charged until a provider approves you, and the consult is free if you go ahead
  • One inclusive price covering consult, medication, supplies, shipping and support
  • LegitScript certified, all 50 states, cancel or change plan at any time
  • NAD+ injections offered alongside the GLP-1 line

Where it loses points

  • The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
  • Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
  • An $80 consultation fee applies if you are approved and then decline
  • Injection only, compounded only, with no published lab programme
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard